Authors: Linkeschova, R.; Raoul, M.; Bott, U.; Berger, M.; Spraul, M.

Source: Diabetic Medicine, Volume 19, Number 9, September 2002 , pp. 746-751(6)

Publisher: Wiley-Blackwell

Abstract:

Aims

To compare glycaemic control, occurrence of acute complications, and diabetes-specific quality of life in Type 1 diabetic patients (on intensified conventional insulin treatment (ICT)) before and after initiation of CSII. Methods

One hundred and three patients (58 women) started CSII between October 1995 and April 1999 in our department. The indication for CSII was optimization of metabolic control and improvement of flexibility of life style (OF group) in 60 patients (58%), and prevention of severe hypoglycaemia (HY group) in 43 patients. Mean age at initiation of CSII was 33 ± 11 years (OF 33 ± 10, HY 33 ± 11 (mean ± sd)), diabetes duration 18 ± 9 years (OF 16 ± 9, HY 20 ± 9). Three patients stopped CSII, mean duration of CSII of the remaining 100 patients was 1.8 ± 1.2 years. The occurrence of hypoglycaemia, ketoacidosis and skin abscesses was assessed retrospectively for the 12 months before starting CSII, and recorded continuously during CSII. Quality of life was assessed with a validated, diabetes-specific questionnaire before and after CSII in 50 patients. Results

The incidence of serious hypoglycaemia (any external help) was reduced from 1.23 (OF 0.0; HY 2.93) during ICT to 0.29 cases/patient per year (OF 0.09; HY 0.55) during CSII. The incidence of severe hypoglycaemia (SH) (treated with i.v. glucose or glucagon injection) fell from 0.70 (OF 0.0; SH 1.67) during ICT to 0.06 cases/patient per year (OF 0.02; HY 0.12) during CSII. HbA_1c improved from 7.7 ± 1.1% to 7.2 ± 1.0% (P < 0.001) (OF 7.8% vs. 7.2%; HY 7.6% vs. 7.2%). During CSII the incidence of abscesses was 0.11 and of ketoacidosis 0.01 cases/patient per year. Quality of life assessments showed significant improvement in all parameters during CSII. Conclusions

In our cohort of Type 1 diabetic patients, we observed a substantial decrease of hypoglycaemia along with a significant fall of HbA_1c. Quality of life on CSII was improved when compared with ICT.

Keywords: hypoglycaemia; CSII; insulin pump therapy; quality of life

Document Type: Research article

DOI: http://dx.doi.org/10.1046/j.1464-5491.2002.00713.x

Affiliations: 1: Department of Metabolic Diseases and Nutrition (WHO-Collaborating Centre for Diabetes), Heinrich-Heine-University, Düsseldorf, Germany

Publication date: 2002-09-01

Related content

• In this: publication
• By this: publisher
• In this Subject: Internal Medicine
• By this author: Linkeschova, R. ;  Raoul, M. ;  Bott, U. ;  Berger, M. ;  Spraul, M.

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers